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Abstract:  Background and Objective: Many clinicians will not treat patients presenting with bisphosphonate-related   
osteonecrosis of the jaw following long-term use of bisphosphonates because of the lack of predictable outcomes.  
Materical and Methods: The patient presented with pain from a nonhealing lesion in the posterior maxilla following  
extraction of the maxillary right third molar. The lesion had not responded to any conventional dental treatment. The  
patient had suffered from breast cancer, and her treatment included several years of therapy with Zometa (zoledronic 
acid), a bisphosphonate. 
Results: The patient stopped taking Zometa and commenced rinsing with phosphate buffer–stabilized 0.1% chlorine   
dioxide–containing mouthwash. After 5 months, changes in the morphology of the lesion were noted and the soft tissue 
had closed over the open wound.  
Conclusion:  Cessation of bisphosphonate therapy and usage of  a phosphate buffer–stabilized 0.1% chlorine   
dioxide–containing mouthwash lessened the patient’s pain and resulted in closure of the soft tissue lesion.  
Keywords: Bisphosphonate, Zometa, Osteonecrosis of the Jaw, Breast cancer, Cancer.  
INTRODUCTION 
Breast cancer is a frightening condition for women, al-
though it is one of the most treatable cancers if detected 
early. Breast cancers occur as a result of genetic abnormali-
ties (e.g. , mutations of the BRCA1 and BRCA2 genes) that 
happen as a result of the aging process and life in general [1, 
2]. However, other factors also play a role in breast cancer 
risk, including the presence of a first-degree relative who has 
had breast cancer. Exposure to estrogen and progesterone 
can also increase the risk of breast cancer somewhat, de-
pending on a woman’s lifetime exposure, the types of hor-
mones used (beyond those that occur naturally), and the 
method of administration [3]. 
Surgery is the primary treatment for breast cancer, al-
though it may be combined with chemotherapy, hormone 
therapy, and radiation therapy. Because some breast cancer 
treatments can cause bone loss (osteoporosis), many women 
being treated for breast cancer are also prescribed a bisphos-
phonate (BP). Some BPs, in addition to helping slow bone 
loss, can also help treat breast cancer; Raloxifene, a drug 
frequently used to reduce osteoporosis in women, has been 
shown to be effective in reducing invasive breast cancer by 
about 50% [4]. However, treatment with BPs is not without 
side effects, and BP-related osteonecrosis of the jaw 
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(BRONJ) has been reported frequently. Researchers believe 
that BRONJ may develop because BPs stop the body from 
repairing microscopic damage to the jawbone that can hap-
pen during routine dental procedures or from everyday wear 
and tear. However, it is still not clear why ONJ occurs in 
some people and not in others [1]. Breast cancer patients 
with a history of long-term use of intravenous BPs are at risk 
for complications related to ONJ. Tooth extraction has been 
reported as one of the major precipitating factors for ONJ 
[5].
 Other contributing factors, such as radiation therapy and 
invasive surgical procedures, have also been discussed [6]. 
Reports of ONJ have become increasingly common since 
2003 [7-10], and the incidence of jaw necrosis in cancer pa-
tients who are on BPs is approximately 6% to 7% [5, 6, 11-
14]. Many cases of ONJ have been described; individual 
authors reported 63, 17, 10, and 10 cases of ONJ, respec-
tively [5, 6, 8, 11]. However, treatment of ONJ is problem-
atic and unpredictable. Therefore, the authors report here on 
their successful treatment of a patient who developed 
BRONJ following extraction of the maxillary right third mo-
lar, which left a nonhealing region in the posterior maxilla. 
The patient had been on long-term intravenous BPs and pre-
sented with a chief complaint of aches and pain along with a 
“sticky, paint-like smell” in the mouth. 
PATIENT REPORT 
The patient was a 38-year-old woman from South Asia 
who had been diagnosed with breast cancer in 1997. She had 
moved to the United States in 2000. Consultation with the 
patient’s oncologist revealed that the patient had been on a 164     The Open Dentistry Journal, 2011, Volume 5  Soolari and Soolari 
monthly protocol of 4 mg of zoledronic acid (Zometa) intra-
venously from 2002 until  2009, when the maxillary right 
third molar was extracted. Three months after the extraction, 
the patient complained of aches and pain in the posterior 
right maxilla. Clinical oral evaluation revealed a 3  3  2-
mm BRONJ lesion (Fig. 1) associated with the palatal aspect 
of the area of the extracted tooth. The patient was treated 
with amoxicillin clavulanate (500 mg orally three times per 
day for 10 days) and chlorhexidine rinse (0.12% twice daily 
for 30 seconds). The patient responded positively and stated 
that she felt better. The aching disappeared, but the open 
wound remained and was plaque retentive and a nuisance to 
the patient.  
Consultation with the patient’s oncologist resulted in dis-
continuation of Zometa treatment. The authors then in-
structed the patient to rinse with phosphate buffer–stabilized 
0.1% chlorine dioxide–containing (PBSCD) mouthwash 
(CloSYS II, Rowpar Pharmaceuticals) for 30 seconds three 
times a day. Five months later, the patient presented with 
almost complete soft tissue healing over the previously ex-
posed necrotic bone (Fig. 2). The patient was happy with the 
mouthwash and stated that the rinse helped her to feel better 
about the area. 
DISCUSSION 
Patients with breast cancer are often treated intravenously 
with zoledronic acid or other BPs to suppress osteoclast ac-
tivity. As many studies have suggested, patients who receive 
intravenous BP therapy along with additional chemotherapy 
and corticosteroids are at a high risk for ONJ [15]. The pre-
sent patient received zoledronic acid on a monthly basis 
from 2002 to 2009. The discontinuation of zoledronic acid 
treatment in January 2009 appeared to help, in contrast to the 
findings of Ruggiero et al, who stated that “there is no evi-
dence to suggest interrupting bisphosphonate therapy will 
prevent or lower the risk of ONJ” [8]. However, since the 
half-lives of various BPs have been reported to range from 
147 hours (in plasma levels [16]) to a very long 10 years (in 
bone [17]), it is possible that cessation may help in such 
cases. 
The intravenous BP used in the present patient were of a 
nitrogen-based nature [18] and is commonly known as zole-
dronic acid [18-20]. Zoledronic acid and other nitrogen-
based BPs, such as pamidronate [21], possess a scaffold, 
which presents with a nitrogen motif as one of its side chains 
[18]. This allows these drugs to work as better antagonists of 
bone resorption than their non–nitrogen-containing counter-
parts [18, 20]. However, long-term use of zoledronic acid 
has a cumulative risk factor for ONJ that climbs with an in-
crease in infusion levels—from 6.7% after 20 treatments to 
31.7% after escalation to 36 treatments [22]. The likelihood 
of zoledronic acid to produce ONJ alone was also compared 
to that of other BPs, and a 9.5-fold greater risk has been re-
ported [23]. Median time to onset of ONJ is also shorter for 
zoledronic acid than for pamidronate: 12 months versus 24 
months, respectively [20, 24].  
Patients who have received oral BP treatment may also 
be at risk for developing ONJ but to a lesser degree than 
their intravenously treated counterparts [8, 25, 26]. Rose et al 
stated that, although “strong clinical research is lacking,” it 
remains true that patients taking oral BPs remain at risk of 
ONJ if their therapy exceeds 3 years [26]. Ruggiero con-
curred [7, 8], and these experts suggest that although the risk 
is rare, it is necessary for those patients who have endured 
oral BP therapy for at least 3 years to receive the same pre-
cautionary treatments as their intravenously treated counter-
parts. Rose et al also stressed the importance of coordination 
between a patient’s health care providers to prevent compli-
cations related to any type of dental treatment—surgical or 
otherwise [8, 26].  
  Because BRONJ has been reported extensively since 
2003 [7-10], the question should be asked of whether the 
potential risk of harming the jawbone is balanced by the re-
ward of the stronger skeleton overall provided by BP treat-
ment [27]. During a minisymposium on BPs and ONJ held in 
2006, Somerman and McCauley suggested several reasons 
why the jaws are affected [27]. First, unlike long bones and 
vertebrae, the maxilla and mandible are formed primarily via 
intramembranous bone formation [6, 27] and second, in con-
 
Fig. (1). BRONJ lesion that developed following tooth extraction. 
 
Fig, (2). Wound closure after 5 months of treatment with PBSCD 
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trast to the red marrow found in long bones, ribs, and verte-
brae, the jaw contains fatty marrow and localized hema-
topoietic marrow, which is found in adults [10, 11, 28]. The 
presence of a hematopoietic environment in the skeleton is 
likely protective in the healing response of the bone—thus, 
the absence thereof in the oral cavity may be a predisposing 
factor to complications [6, 12, 13, 27]. This, in addition to 
the notion that the bones of the jaw are continuously exposed 
to microorganisms, may explain the ineffectiveness of an 
antibiotic in reaching its target to manage a non healing re-
gion of ONJ. Somerman and McCauley also noted the sensi-
tivity of oral tissues to alterations in phosphate and pyro-
phosphate levels, as well as to changes in the phos-
phate/pyrophosphate ratio, as another predisposing factor for 
emerging ONJ. In addition to what has already been men-
tioned, the authors suggested that BPs may play a role in 
reducing vascularity of the target tissue, such as the jaw, 
because of the effect BPs have on osteoclasts [9, 10, 13, 14, 
27, 29].  
As one of the major precipitating factors for ONJ, extrac-
tion has been reported to be associated with the onset of ex-
posed ONJ lesions in 70% [5, 29] to 100% of cases [30]. 
Other factors, such as radiation therapy and invasive surgical 
procedures [6], have been noted as predisposing influences 
as well. Newer information indicates that the etiology of 
ONJ is likely multifactorial [15, 31, 32], including but not 
limited to corticosteroids, chemotherapy, radiotherapy, jaw 
trauma, denture trauma, infection, and cancer [7, 8, 17, 33, 
34].  
Periodontal disease was found to be the most common 
dental comorbidity in cases of BRONJ [35]. In 2005 the 
American Academy of Periodontology classified ONJ risk 
factors into “definite,” “probable,” and “additional” risk fac-
tor categories [36]. Those that are considered “definite” risk 
factors for ONJ are major trauma to the jawbone area, frac-
tures, dislocations, sickle cell disease, Caisson disease, Gau-
cher disease, irradiation, chemotherapy, and arterial disease. 
ONJ risk factors classified as “probable” deal primarily with 
corticosteroids, alcohol consumption, smoking habits, lupus, 
kidney disease, liver disease, lipid disturbances, connective 
tissue diseases, and pancreatitis. “Additional” risk factors 
include categories such as a history of cancer, gender 
(women are more predisposed), advanced age, the presence 
of edentulous regions, surgical dental procedures, prior in-
fection of the jaw area, combined cancer therapy, blood dy-
scrasias, anemia, and coagulopathy [36].  
Sedghizadeh et al. [37] explored the role of biofilm and 
hypothesized that the pathogenesis of ONJ may represent a 
biofilm-mediated infectious disease in the context of BP 
therapy and that therefore a potential target for therapy 
should include antibiofilm modalities [37]. Grootvelt et al. 
presented evidence for the microbicidal activity of a chlorine 
dioxide–containing oral rinse that demonstrated the ability of 
the oral rinse to diminish salivary levels of Streptococcus 
mutans and lactobacilli [38]. Its positive impact on malodor 
was investigated recently by Shinada et al. [39]. The authors 
concluded that rinsing with chlorine dioxide–containing oral 
rinse reduced malodor significantly. Moreover, the mouth-
wash appeared to be effective in reducing plaque, the accu-
mulation of tongue coating, and counts of Fusobacterium 
nucleatum in saliva [39]. The aforementioned studies suggest 
that the inhibitory effect of chlorine dioxide–containing 
mouthwash on harmful oral bacteria may play a positive role 
in sequestration of necrotic bone, wound healing, and resolu-
tion of BRONJ.  
In the present situation, it is not clear when and how the 
necrotic bone was sequestered from the area, because the 
patient did not state that she had lost bone from her palate. 
The authors speculate that sequestration took place, but be-
cause of the small size of the lesion, the patient could not 
feel it or detect it. Although, as mentioned earlier, there is 
disagreement regarding whether cessation of BPs may help 
to prevent ONJ [8], it can be speculated that in this case a 
combination of discontinuation of zoledronic acid and initia-
tion of the rinsing protocol with PBSCD helped resolve the 
non healing lesion. The authors are in agreement with 
Soolari et al [40] and Marder and Marder’s suggestion that 
PBSCD mouthwash has anti-inflammatory and antifungal 
activities and has the potential to facilitate release of necrotic 
bone and closure of an open wound [41].  
On a positive note, a recent study observed favorable re-
sults in the treatment of BP-associated osteonecrosis with a 
combination of marginal resection and platelet-derived 
growth factors, with most patients showing complete wound 
healing [35]. However, treatment and supportive therapy of a 
non healing lesion for patients suffering from BRONJ con-
tinue to present a major challenge to health care providers. 
The present protocol represents a noninvasive treatment op-
tion for patients with BRONJ.  
RECOMMENDATIONS 
Through continued cooperation between healthcare pro-
viders, dental surveillance, prophylactic care, and most im-
portant, early diagnosis and management, morbidity result-
ing from ONJ caused by BP use may be reduced greatly or 
even eliminated in the future [21].  
Although there is currently no proven effective treatment 
for BRONJ lesions, the authors recommend the following.  
1)  Close coordination is essential between medical and 
dental practitioners for patients who are starting BP 
therapy, those who have started BPs but not devel-
oped ONJ, and patients who have already developed 
ONJ [21]. All invasive dental procedures should be 
completed well in advance of the initiation of intrave-
nous BP treatment, with continued dental supervision 
thereafter. Patients at the highest risk are cancer pa-
tients who are receiving a combination of chemother-
apy and corticosteroid therapy, long-term users of BP 
(particularly zoledronic acid), removable partial den-
ture users, and patients with poor oral hygiene and 
periodontal disease [21].  
2)  The use of an alternate infusion schedule for zole-
dronic acid is recommended to reduce the risk of ONJ 
in patients with breast cancer. Treatments should be 
conducted monthly during the first year and every 3 
months thereafter, rather than on the standard sched-
ule, in which infusions are received on a monthly ba-
sis for an indeterminate period [34].  166     The Open Dentistry Journal, 2011, Volume 5  Soolari and Soolari 
3)  In addition, if ONJ has already emerged, antibiotics 
should be prescribed before and after any pending 
dental procedure, along with a chlorhexidine rinse, to 
prevent complications or further progression of the 
ONJ lesion [7, 8, 26]. 
4)  A fixed partial denture is recommended over a re-
moval partial denture to reduce the likelihood of the 
emergence of ONJ by denture-induced trauma [8]. 
5)  Frequent dental prophylaxis is advised to eliminate 
plaque from the necrotic region and to reduce antigen 
loads in general [21]. 
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